Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00298038
Recruitment Status : Completed
First Posted : March 1, 2006
Results First Posted : August 14, 2019
Last Update Posted : September 18, 2019
Sponsor:
Information provided by (Responsible Party):
Bausch Health Americas, Inc.

Brief Summary:
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).

Condition or disease Intervention/treatment Phase
Hepatic Encephalopathy Drug: Rifaximin Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 299 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
Actual Study Start Date : December 19, 2005
Actual Primary Completion Date : August 15, 2008
Actual Study Completion Date : August 15, 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Rifaximin

Arm Intervention/treatment
Experimental: Rifaximin
Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
Drug: Rifaximin
Oral
Other Name: Xifaxan®

Placebo Comparator: Placebo
Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
Drug: Placebo
Oral




Primary Outcome Measures :
  1. Time To The First Breakthrough Overt HE Episode [ Time Frame: Baseline up to 6 Months (168 days) ]
    Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit. Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome. Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier. The number of events of a first breakthrough overt HE episode during the treatment interval is presented.


Secondary Outcome Measures :
  1. Time To First HE-related Hospitalization [ Time Frame: Baseline up to 6 months ]
    Time to first HE-related hospitalization is defined as the duration (number of days) between the first dose of study drug and the date of first HE-related hospitalization. Participants who discontinued prior to hospitalization due to HE and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of participants with their first HE-related hospitalization per interval is presented. The number of events of the first HE-related hospitalization during the treatment interval is presented.

  2. Time To Any Increase From Baseline In Conn Score [ Time Frame: Baseline up to 6 months ]
    Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score. Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state). Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented.

  3. Time To Any Increase From Baseline In Asterixis Grade [ Time Frame: Baseline up to 6 months ]
    Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade. Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice. Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions). Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented.

  4. Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment [ Time Frame: Baseline, 6 months (End Of Treatment) ]
    The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue).

  5. Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment [ Time Frame: Baseline, Month 6 (End Of Treatment) ]
    Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168. Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must sign an Informed Consent Form
  • In remission from past HE
  • Uses appropriate birth control measures
  • More than or equal to 18 years of age
  • Must have potential to benefit from treatment
  • Recent prior HE episodes
  • Capable and willing to comply with all study procedures
  • Participant has personal support available
  • Has a certain Model End Stage Liver Disease (MELD) score
  • Recent transjugular intrahepatic portosystemic shunt (TIPS) placement or revision

Exclusion Criteria:

  • Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include
  • Allergies to the study drug or similar drugs
  • Laboratory abnormalities
  • Recent participation in another clinical trial
  • History of non-compliance
  • Pregnant or at risk of pregnancy, or is lactating
  • Recent alcohol consumption
  • Active bacterial or viral Infections
  • Bowel issues
  • Active malignancy
  • On a prohibited medication
  • Liver transplant expected in near term
  • Lactulose intolerance
  • Participant shows presence of intestinal obstruction or has inflammatory bowel disease
  • Ongoing or recent GI bleed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00298038


Sponsors and Collaborators
Bausch Health Americas, Inc.
Investigators
Layout table for investigator information
Study Director: Lindsey Mathew Bausch Health Companies

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bausch Health Americas, Inc.
ClinicalTrials.gov Identifier: NCT00298038    
Other Study ID Numbers: RFHE3001
First Posted: March 1, 2006    Key Record Dates
Results First Posted: August 14, 2019
Last Update Posted: September 18, 2019
Last Verified: September 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatic Encephalopathy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Rifaximin
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents